Diagnosis and surgical treatment of tumor-induced osteomalacia—a literature review and a case report

Peikai Huang, Mengqiang Xiao*, Meng Zhang, Jun Chen, Jingzhi Ye, Meiyi Zhao and Jiahui Tang

Abstract

Background: Tumor-induced osteomalacia (TIO) is a rare condition with fewer than 500 cases reported in the literature although described. Phosphaturic mesenchymal tumor (PMT) is often unrecognized cause of hypophosphatemia. This case report aims to highlight such a rare association which warrants clinical and radiologist attention.

Case: A 51-year-old man had pain in his feet 2 years prior to the most recent presentation in our clinic. The patient experienced increasingly severe body aches and pain, which affected the feet, hips, knees, ribs, waist, and shoulders. MRI and CT led to the diagnosis of multiple insufficiency fractures. Laboratory tests showed that inorganic phosphate (IP) levels had decreased to 0.52 mmol/L (0.81–1.45 mmol/L), while alkaline phosphatase (ALP) had increased to 216 U/L (38.0–126.0 U/L). Positron emission tomography computed tomography showed tumor-derived hypophosphate osteomalacia of the right iliac wing; surgical resection was performed. Markers of bone metabolism and bone density returned normal postoperative, after 9 months follow-up.

Conclusion: The possibility of tumor-induced osteomalacia should be considered if unexplained joint pain, decreased bone mineral density, increased ALP and insufficiency fractures, and no similar family history are found in adult patients. Surgical resection of the tumor is the key to the treatment.

Keywords: Phosphaturic mesenchymal tumors, Tumor-induced osteomalacia
osteoarthropathy, or insufficiency fracture, as well as its atypical clinical manifestations.

Case presentation
In February 2018, the patient came to our hospital with the complaint of pain between the toes with no obvious cause, as well as impaired mobility and hip discomfort. Laboratory tests showed a uric acid (UA) level of 503 μmol/L (202.3–416.5 μmol/L) and an IP level of 102 mmol/L (0.81–1.45 mmol/L); other laboratory test results were normal. In August 2018, magnetic resonance imaging (MRI) of both feet (i.e., the base of the first metatarsal of the left foot and the proximal segment of the second metatarsal and second metatarsal head of the right foot (Fig. 1-1, 1-2)) led to the diagnosis of insufficiency fractures. After multiple outpatient treatments for gout and foot fasciitis, the patient's symptoms did not substantially improve. Lumbosacral pain, stiffness, and discomfort gradually appeared; furthermore, the symptoms of bilateral chest muscle pain, breathing difficulty, and coughing...
were aggravated. The patient was treated for a bulging disc, but his symptoms did not improve. He was hospitalized in April 2019 and diagnosed with gouty arthritis, aseptic necrosis of the left femoral head (Fig. 1-3), and osteopenia (overall lumbar spine T value = 2.0, hip joint T value = 0.8). He received clinical treatments for pain, elevated uric acid level, and osteoporosis. The symptoms improved and he was discharged from the hospital; however, he continued to experience pain in multiple joints. By September 2019, the patient’s clinical symptoms had worsened; thus, he was hospitalized in the Fifth Affiliated Hospital of Sun Yat-sen University (Zhuhai, China) for insufficiency fractures of both the tibial plateau and thoracolumbar spine. Dual-source CT showed gouty arthritis of both feet and laboratory tests showed an alkaline phosphatase (ALP) level of 158 U/L, which led to the diagnosis of myopathy. The patient was treated for his symptoms, then discharged. Beginning in January 2020, the patient experienced pain in multiple joints throughout the body including the feet, hips, knees, ribs, waist, and shoulders; he also experienced poor mobility. Outpatient treatments for dry mouth, dry eyes, rash, and oral ulcers were ineffective. The patient was hospitalized in May 2020 in the orthopedics department. No obvious abnormalities were found in the bilateral femur,ibia and fibula, hip, knee, or ankle joints. Chest CT showed fractures on ribs 1, 2, and 5–7 on the right side (Fig. 1-4); ribs 2 and 3 on the left side; the thoracic spine (T4–5,T9);and the first vertebra of the lumber spine (L1) (Fig. 1-5, 1-6, 1-7, 1-8). Laboratory examination showed that the IP level had decreased to 0.52 mmol/L, ALP level had increased to 216.4 U/L, osteocalcin (OST) 23.02 μg/L (9.80–26.40 μg/L), type I collagen amino-terminal extension of peptides (TPINP) 113.0 ng/ml (21.6 ng/ml), β-C-terminal telopeptide of type I collagen (β-CTx) 0.69 μg/ml (≤ 0.704 μg/ml) and UA level had increased to 477 μmol/L, parathyroid hormones (PTH) 16.50 pg/ml (15–65 pg/ml). There were no obvious abnormalities in routine blood test, coagulation, erythrocyte sedimentation rate, or thyroid function findings. The stool test findings were normal. Components of bone metabolism were re-evaluated after 7 days of hospitalization: IP had decreased to 0.36 mmol/L and ALP had increased to 205.7 U/L. Multidisciplinary consultation suggested TIO. Positron emission tomography-computed tomography (PET-CT) was performed and revealed presence of the right iliac active nodules. Tumor-derived low phosphorus osteomalacia was considered (Fig. 1-1, 1-2, 1-3).

Preoperative imaging
MRI showed an abnormal signal focus on the anteromedial lower right iliac bone; based on the patient’s clinical history, this focus was presumed to be a PMT (Fig. 2-1, 2-2, 2-3). Bone density examination showed that the overall T value of the lumbar spine was −1.6, while the T value of the hip joint was −2.6, suggesting osteoporosis of the hip joint. CT showed bone hyperplasia of the right iliac bone, with no obvious abnormalities.

Preoperative laboratory examination
Laboratory tests showed that ALP increased to 185.3 U/L, while IP increased to 0.54 mmol/L. Routine blood and stool tests showed no obvious abnormalities. Furthermore, there were no obvious abnormalities in coagulation, erythrocyte sedimentation rate, fasting blood glucose, rheumatoid factor, myocardial enzyme, electrolyte, or any other preoperative test results.

Surgical resection of pathology in August 2020
The fragmented bone tissue was subjected to pathology analysis. Tumor cells were visible in the bone trabecula, with diffuse infiltrating growth; this was characterized by abundant uniform oval and short spindle-shaped cells distributed around the blood vessel in a sheet and band. There were no obvious abnormalities in the tumor cells, and nuclear divisions were occasionally observed. The interstitium was rich in blood vessels, some of which were hemangiopericytoma-like blood vessels; bone-like matrix was evident.

Immunohistochemistry results
CD34 (rich in blood vessels), SMA(−), Desmin(−), Ki67(1%−), S-100(−), STAT6 cytoplasm (+), CK(−), Vimentin(+), CD56(+), CD68(−), NSE(part +), CD99(−), ERG(part +), FLI1(−), D2-40(−), STAB2(+)(Fig. 3-4).

Pathological diagnosis
Consistent with the blood biochemical test results, clinical manifestations, imaging data, and immunohistochemical results, the pathological morphology was suggestive of PMT.

Review in May 2021
Four components of bone metabolism were analyzed: ALP, 102 U/L; osteocalcin, 23.2 μg/L (9.80–26.40 μg/L); calcium (Ca), 2.32 mmol/L (2.10–2.55 mmol/L); and IP, 1.22 mmol/L. Bone density evaluation showed that the overall T value of the lumbar spine was −0.5, while the T value of the hip joint was −0.3, indicating normal bone quality.
Diagnosis and treatment process (Table 1)

Follow-up and outcomes
Pathologically, distal-type PMT was diagnosed. There has been no disease recurrence, and no treatment such as chemotherapy or radiotherapy was required. On May 2021, four components of bone metabolism showed normal.

Discussion
Hypophosphatemic osteomalacia is mainly divided into hereditary and acquired types. Acquired hypophosphatemic osteomalacia is divided into drug-induced and neoplastic subtypes; neoplastic hypophosphatemia osteomalacia is a rare paraneoplastic syndrome [5]. Clinical manifestations are unexplained bone pain, muscle weakness, fractures, and bone deformities. Because its early clinical manifestations are non-specific, complex, and diverse, the rates of clinical misdiagnosis and missed diagnosis are high [6]. The most frequent misdiagnoses are intervertebral disc herniation, spondylarthritis (including ankylosing spondylitis), and osteoporosis. Wu N et al. [7] report 43.1% (62/144) of hypophosphatemia cases are overlooked and their diagnoses are missed. Most studies have shown that the excessive secretion of phosphate-regulating factors by tumors, especially fibroblast growth factor-23, acts on the proximal convoluted tubules; this indirectly inhibits phosphate reabsorption by the kidneys. The effects include increased renal phosphorus excretion, high urinary phosphorus, and a low level of phosphate in the blood, leading to acquired hypophosphatemia osteomalacia; conventional phosphorus supplementation is ineffective [2, 8]. These clinical signs are caused by PMTs of the soft tissue and bone, which are usually benign. Recently, malignant neoplasms

Fig. 2  2-1 T2WI pressure-fat in 2019, right iliac bone abnormal signal (arrow). 2-2 and 2-3 2020 T1WI, T2WI pressure-fat with increased iliac bone abnormal signal range. 2-4 2020 normal CT
such as small cell lung carcinoma [9], colon adenocarcinoma [10], prostate adenocarcinoma [11], renal cell carcinoma [12], and multiple myeloma [13] have been associated with acquired hypophosphatemia osteomalacia [14].

After a diagnosis of TIO is established, it is crucial to locate the PMT, because surgical excision of the tumor is the only definitive curative treatment. Because the tumor is small and indolent, affected patients’ medical

Table 1  Sequence of events throughout diagnosis and follow-up treatment process

| Year, month | Diagnosis and treatment process |
|-------------|---------------------------------|
| 2018 February | Hyperuricemia, pain in the second metatarsophalangeal joint of the right foot. |
| 2018 June | Insufficiency fractures of the base of the first metatarsal bone of the left foot, and the second metatarsal head of the right foot. |
| 2019 January | Lumbar degenerative osteoarthropathy, L4/S intervertebral disc bulging, L5 vertebral body left spondylolysis. |
| 2019 April | Chest CT: normal; MRI: avascular necrosis of the left femoral head; bone density: osteoporosis (lumbar spine T-2.0, hip joint T-0.8); ALP = 190 U/L, UA = 460 μmol/L. |
| 2019 September | MRI: double tibial plateau, thoracolumbar insufficiency fracture, double foot; CT: gouty arthritis; ALP = 158 U/L. |
| 2020 May | MRI and/or CT: multiple insufficiency fractures of the thoracolumbar and ribs; bone density: osteoporosis (lumbar spine T-2.3, hip joint T-2.6); ALP increased to 216 U/L, UA = 477 μmol/L, IP = 0.52 mmol/L, parathyroid hormone = 116.5 pg/mL, bone metabolism: ALP = 205.7 U/L, normal calcium, and normal magnesium; clinical diagnosis of TIO. |
| 2020 August | PET-CT: right iliac wing TIO nodules; MRI: right iliac bone abnormal nodules; ALP increased to 185.3 U/L; IP decreased to 0.50 mmol/L; surgical resection. |
| 2021 January | ALP = 102 U/L (normal), osteocalcin = 23.2 μg/L, calcium = 2.32 mmol/L, IP = 1.22 mmol/L (normal). Bone density: overall T value of the lumbar spine was −0.5, T value of the hip joint was −0.3, and bone quality was normal. |

CT computer tomography, MRI magnetic resonance imaging, UA uric acid, ALP alkaline phosphatase, IP inorganic phosphate, TIO tumor-induced osteomalacia, PET-CT positron emission tomography–computed tomography
histories and physical examinations seldom reveal a lump or bump. Additionally, approximately 2% of patients may have multifocal disease at initial presentation [2].

Imaging is important for tumor localization. Tumors are usually small, especially in distal extremities, and can easily be missed by CT or MRI [15]. The morphological features of PMTs are usually similar to other common bone or soft tissue tumors. Using conventional CT and MRI, it is difficult to distinguish whether a tumor has secretory function [16]. Some clinicians have recommended molecular imaging as an initial imaging tool for the detection and localization of TIO. TIO pathogenic tumors mostly originate from mesenchymal tissues and express somatostatin receptors. Somatostatin receptor imaging has become an important means to explore TIO pathogenic tumors. Relevant imaging agents include 111In-octreotide, 99mTc-hydrazinonicotinamide-Tyr3-OCT, and 68Ga-labelled somatostatin analogues. Ga-68 DOTATATE, used during PET-CT, has high diagnostic sensitivity of 92.6–98.1% [1, 2, 4, 9, 17]. Selective somatostatin receptor imaging with Ga-68 DOTATATE PET-CT has been established as a preferred primary imaging modality [18].

Currently, there are no guidelines for the treatment of TIO. For this disease, most clinicians focus on treating the cause; generally, patients can be cured after complete removal of the tumor [1, 19]. Tumor recurrence occurs in fewer than 5% of patients with TIO [6, 20]. The lung is a common site of metastasis. The course after metastasis is variable, and survival of up to 30 years has been reported [20].

This case demonstrates the typical chronological progression of TIO, in which the diagnosis and tumor localization are challenging for clinicians and radiologists. Our patient initially experienced pain between the toes and received treatment for gouty arthritis, which provided some symptomatic improvement. His laboratory test results were normal, which increased the risk of missed diagnosis. Then, progressive bone and joint pain, substantial muscle weakness, hyperuricemia, and atypical inflammatory back pain occurred. Inflammation indicators were normal. Osteoporosis, multiple insufficiency fractures, and subsequent treatments of gouty arthritis and osteoporosis were ineffective, suggesting the presence of metabolic bone disease. Further screening for markers of bone metabolism: ALP level had increased to 216.4 U/L and TPINP level had increased to 113.0 ng/ml, OST and β-CTx level were normal. Additional analyses were conducted to identify the cause of hypophosphatemia. The patient had no familial medical history suggestive of a genetic aetiology; he also had no distinctive medication history. Fanconi syndrome caused by systemic diseases (e.g., amyloidosis or Sjögren’s syndrome) was excluded, the patient’s blood sugar and blood routine test levels were normal. Notably, conventional CT and MRI easily missed the diagnosis in this patient. After the tumor had been removed, Oral calcium supplementation, calcitriol capsules, and traditional Chinese medicine in the treatment of osteoporosis and phosphorus supplementation were administered. The patient’s symptoms of bone pain and muscle weakness were substantially relieved, and ALP, calcium, and bone density returned to normal. Thus, the patient’s osteomalacia-related hypophosphatemia had been caused by the tumor.

Conclusion
Tumor-induced osteomalacia (TIO) is a rare disease. The early clinical manifestations are non-specific, and routine laboratory examinations show no characteristic indicators; these are the main reasons for misdiagnosis in patients with TIO. When a patient has unidentified limb joint pain, low back pain, and muscle weakness, clinicians should consider laboratory assessments of bone metabolism abnormalities, imaging examinations to identify osteoporosis and insufficiency fractures, and a detailed physical examination to exclude primary and drug-induced causes. Adequate tumor screening, especially PET-CT examination of soft tissue and bone tumors to facilitate early diagnosis and early surgical resection, is important for osteomalacia prognosis. In addition, timely pathological examination can effectively prevent or reduce misdiagnosis.

Abbreviations
PMT: Phosphaturic mesenchymal tumor; TIO: Tumor-induced osteomalacia; MRI: Magnetic resonance imaging; CT: Computed tomography; ALP: Alkaline phosphatase; PET-CT: Positron emission tomography–computed tomography; UA: Uric acid; OST: Osteocalcin; TPINP: Type I collagen amino-terminal extension of peptides; β-CTx: β-C-terminal telopeptide of type I collagen; IP: Inorganic phosphate; PTH: Parathyroid hormones.

Acknowledgements
We greatly appreciate the assistance of the staff in the Department of Hepatobiliary Surgery and Pathology at Zhuhai Hospital of Guangdong Hospital of Traditional Chinese Medicine for their help and efforts.

Authors’ contributions
PK Huang was involved in drafting the manuscript; M Zhang, JZ Ye, and JH Tang were involved in acquisition of data and preparing the figures. MQ Xiao designed the manuscript. MQ Xiao and J Chen were involved in analysis and interpretation of data. PK Huang and MQ Xiao were involved in review and revised the manuscript. All authors have read and approved the final manuscript.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials
Some or all data, models, or code generated or used during the study are available from the corresponding author by request (MQ Xiao, Email: xmqzh uha163.com).
Declarations

Ethics approval and consent to participate
This study was approved by the ethics committee of Guangdong Hospital of Traditional Chinese Medicine.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and accompanying images.

Competing interests
The authors declare that they have no competing interests.

Received: 22 November 2021   Accepted: 30 December 2021
Published online: 28 January 2022

References

1. Dadoniene J, Miglinas M, Miltiniene D, Vajauskas D, Seinin D et al (2016) Tumour-induced osteomalacia: a literature review and a case report. World J Surg Oncol 14(1):4. https://doi.org/10.1186/s12957-015-0763-7

2. Richardson AL, Richardson OK (2019) Phosphaturic mesenchymal tumor: Case report. Radiol Case Rep 14(12):1518–1524. https://doi.org/10.1016/radioc.2019.09.027

3. Mc CR (1947) Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med 16(1):33–46

4. Kumar S, Diamond T (2020) Lessons learnt from delayed diagnosis of FGF-23-producing tumour-induced osteomalacia and post-operative hungry bone syndrome. Bone Rep 12:100276. https://doi.org/10.1016/j.bonr.2020.100276

5. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28(1):1–30. https://doi.org/10.1097/00000478-200401000-00001

6. Feng J, Jiang Y, Wang Q, Li M, Xing Y et al (2017) The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J 64(7):675–683. https://doi.org/10.1507/endocrj.EJ16-0587

7. Wu N, Zhang Z, Zhou X, Zhao H, Ming Y et al (2020) Mutational landscape and genetic signatures of cell-free DNA in tumour-induced osteomalacia. J Cell Mol Med 24(9):4931–4943. https://doi.org/10.1111/jcmm.14991

8. Obo T, Koriyama N, Tokito A, Ogiso K, Nishio Y (2020) Neurofibromatosis type 1 associated with hypophosphatemic osteomalacia due to hypersecretion of fibroblast growth factor 23: a case report. J Med Case Rep 14(1):56. https://doi.org/10.1186/s13256-020-02381-1

9. Tantisattamo E, Ng RC (2011) Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature. World J Surg Oncol 9(1):887–891. https://doi.org/10.1186/1477-7817-9-887

10. Leaf DE, Pereira RC, Bazari H, Juppner H (2013) Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management. Br J Radiol 90(1079):20150811e. https://doi.org/10.1259/bjr.20150811e

11. Li B, Dong Y, Liu D, Yao Q, Guo S et al (2020) Left maxillary sinus tumour-induced hypophosphatasaemic osteomalacia and combined with thyroid papillary carcinoma: a case report and literature review. Intern Med J 50(6):755–761. https://doi.org/10.1111/imj.14864

12. Zhou Z, Yue H, Xu J, Xu X, Guo Q et al (2018) A case with tumour-induced osteomalacia misdiagnosed as axial spondyloarthritis. Rheumatology (Oxford) 57(12):2242–2243. https://doi.org/10.1093/rheumatology/key255

13. Singh D, Chopra A, Ravina M, Kongara S, Bhatia E et al (2017) Correction to Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management. Br J Radiol 90(1079):20160811e. https://doi.org/10.1259/bjr.20160811e

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.